FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
Skyrizi is first specific interleukin-23 approved to treat Crohn disease.
Crohn Disease
Crohn Disease: Clinical Update on Diagnosis, Pathophysiology, and Treatment
The incidence of Crohn disease is increasing in the US. Experts outline the risk factors, pathophysiology, and symptoms of Crohn disease as well as strategies for diagnosis and treatment of this disease in the primary care setting.
Disparities in the Diagnosis and Management of IBD Among Different Racial and Ethnic Groups
Researchers sought to identify disparities in the care and outcomes of patients with IBD of differing races and ethnicities, in order to improve health care equity.
Assessing Risk for Chronic Inflammatory Diseases in Children of Affected Adults
Study authors assessed registry data to evaluate the risk of developing childhood chronic inflammatory diseases dependent on disease status of the parents.
ASCRS Updates Guidelines on Surgery for Crohn Disease
Researchers state surgery should be considered for patients who demonstrate an inadequate response to medical therapy.
Inflammatory Conditions of Skin, Bowel May Be Linked
Authors say patients with hidradenitis suppurativa should be screened for inflammatory bowel disease.
Guidance Issued for Food Intake in Inflammatory Bowel Disease
Evidence insufficient for recommending changes in diet for complex carbs, refined sugars, wheat, gluten.
Patients with Ulcerative Colitis and Crohn Disease Demonstrate Increased Risk for Psychiatric Illnesses
For both patients with ulcerative colitis and those with Crohn disease, psychiatric diagnoses were more common in those who were elderly (greater than 65 years old), women, and white, and those with psychiatric conditions more frequently had a history of alcohol abuse, tobacco and substance abuse, personality disorder, and corticosteroid use.
Anti-TNFα Agents May Increase Risk for Crohn Disease, Ulcerative Colitis
Treatment with anti-TNFα agents for conditions other than inflammatory bowel disease may increase the risk of developing Crohn disease or ulcerative colitis.
IBD Treatments Compared in Older Patients With Crohn Disease, Ulcerative Colitis
In older patients with inflammatory bowel disease, tumor necrosis factor alpha antagonist therapy and vedolizumab were found to be comparable with regard to both safety and effectiveness.
- Loading...
Loading...
Next post in Gastroenterology Information Center
Loading... 
Loading...